Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma

American Journal of Respiratory and Critical Care Medicine

Volumn 176, Issue 1, 2007, Pages 27-35

  Katoh, Shigeki ^a   Ishii, Naoki ^b   Nobumoto, Atsuya ^a   Takeshita, Keisuke ^b   Dai, Shu Yan ^a   Shinonaga, Rika ^b   Niki, Toshiro ^b   Nishi, Nozomu ^a   Tominaga, Akira ^c   Yamauchi, Akira ^a   Hirashima, Mitsuomi ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b Galpharma Co Ltd   (Japan)

^c KOCHI UNIVERSITY   (Japan)

Author keywords

Airway hyperresponsiveness; Allergy; Experimental model; Galectin 9 ligand

Indexed keywords

ALLERGEN; CELL ADHESION MOLECULE; ECALECTIN; GALECTIN; HERMES ANTIGEN; HYALURONIC ACID; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD; CELL MIGRATION; CONTROLLED STUDY; DRUG MECHANISM; EXTRACELLULAR MATRIX; INHIBITION KINETICS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD44; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; BRONCHIAL PROVOCATION TESTS; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; GALECTINS; HUMANS; HYALURONIC ACID; LEUKOCYTES; MALE; MICE; MICE, INBRED BALB C;

EID: 34447267678     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200608-1243OC     Document Type: Article

References (50)

1. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med 2001;344:350-362.
2. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol 1999;17:255-281.
3. Cohn L, Elias JA, Chupp GL. Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol 2004;22:789-815.
4. Robinson DS. The role of the mast cell in asthma: induction of airway hyperresponsiveness by interaction with smooth muscle? J Allergy Clin Immunol 2004;114:58-65.
5. Lesley J, Hyman R, Kincade PW. CD44 and its interaction with the extracellular matrix. Adv Immunol 1993;54:271-335.
6. Miyake K, Underhill CB, Lesley J, Kincade PW. Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition. J Exp Med 1990;172:69-75.
7. Katoh S, Zheng Z, Oritani K, Shimozato T, Kincade PW. Glycosylation of CD44 negatively regulates its recognition of hyaluronan. J Exp Med 1995;182:419-429.
8. DeGrendele HC, Estess P, Siegelman MH. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 1997;278:672-675.
9. Mohamadzadeh M, DeGrendele H, Arizpe H, Estess P, Siegelman MH. Proinflammatory stimuli regulate endothelial hyalutonan expression and CD44/HA-dependent primary adhesion. J Clin Invest 1998;101:97-108.
10. Katoh S, Matsumoto N, Kawakita K, Tominaga A, Kincade PW, Matsukura S. A role for CD44 in an antigen-induced murine model of pulmonary eosinophilia. J Clin Invest 2003;111:1563-1570.
11. Leffler H. Introduction to galectins. Trends Glycosci Glycobiotech 1997;9:9-19.
12. Perillo NL, Marcus ME, Baum G. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med 1998;76:402-412.
13. Matsumoto R, Matsumoto H, Seki M, Hata M, Asano Y, Kanegasaki S, Stevens RL, Hirashima M. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem 1998;273:16976-16984.
14. Wada J, Ota K, Kumar A, Wallner EI, Kanwar YS. Developmental regulation, expression, and apoptotic potential of galectin-9, a β-galactoside binding lectin. J Clin Invest 1997;99:2452-2461.
15. Matsumoto R, Hirashima M, Kita H, Gleich GJ. Biological activities of ecalectin: a novel eosinophil-activating factor. J Immunol 2002;168:1961-1967.
16. Kageshita T, Kashio Y, Yamauchi A, Seki M, Abedin MJ, Nishi N, Shoji H, Nakamura T, Ono T, Hirashima M. Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer 2002;99:809-816.
17. Hirashima M, Kashio Y, Nishi N, Yamauchi A, Imaizumi T, Kageshita T, Saita N, Nakamura T. Galectin-9 in physiological and pathological conditions. Glycoconj J 2004;19:593-600.
18. Irie A, Yamauchi A, Kontani K, Kihara M, Liu D, Shirato Y, Seki M, Nishi N, Nakamura T, Yokomise H, et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res 2005;11:2962-2968.
19. Kashio Y, Nakamura K, Abedin MJ, Seki M, Nishi N, Yoshida N, Nakamura T, Hirashima M. Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol 2003;170:3631-3636.
20. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury S, Zheng XX, Strom TB, Kuchroo VK. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005;6:1245-1252.
21. Katoh S, Yamauchi A, Hirashima M. Galectin-9 negatively regulates CD44-hyaluronic acid interaction and its role in murine model of bronchial asthma [abstract]. 25th Congress of EAACI 2006:205; Vienna, Austria.
22. Katoh S, Nobumoto A, Takeshita K, Yamauchi A, Hirashima M. Galectin-9 negatively regulates CD44-hyaluronic acid interaction and its role in murine model of bronchial asthma [abstract]. 20th Congress of IUBMB 2006:101; Kyoto, Japan.
23. Nishi N, Itoh A, Fujiyama A, Yoshida N, Araya S-I, Hirashima M, Shoji H, Nakamura T. Development of highly stable galectins: truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. FEBS Lett 2005;579:2058-2064.
24. Komai M, Tanaka H, Masuda T, Nagao K, Ishizaki M, Sawada M, Nagai H. Role of Th2 responses in the development of allergen-induced airway remodeling in a murine model of allergic asthma. Br J Pharmacol 2003;138:912-920.
25. Zheng Z, Katoh S, He Q, Oritani K, Miyake K, Lesley J, Hymam R, Hamik A, Parkhouse RME, Farr AG, et al. Monoclonal antibodies to CD44 and their influence on hyaluronan recognition. J Cell Biol 1995;130:485-495.
26. Lesley J, He Q, Miyake K, Hamann A, Hyman R, Kincade PW. Requirements for hyaluronic acid binding by CD44: a role for the cytoplasmic domain and activation by antibody. J Exp Med 1992;175:257-266.
27. Matsushita N, Nishi N, Seki M, Matsumoto R, Kuwabara I, Liu F-T, Hata Y, Nakamura T, Hirashima M. Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction. J Biol Chem 2000;275:8355-8360.
28. Lohning M, Stroehmann A, Coyle AJ, Grogan JL, Lin S, Gutierrez-Ramos J-C, Levinson D, Radbruch A, Kamradt T. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA 1998;95:6930-6935.
29. Bonecchi R, Bianchi G, Panina-Bordignon P, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Grat PA, Mantovani A, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998;187:129-134.
30. Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998;282:2261-2263.
31. Barnes PJ. Therapeutic strategies for allergic diseases. Nature 1999;402:B31-B38.
32. Ho C-Y, Wong C-K, Ko FW-S, Chan CH-S, Ho AS-S, Hui DS-C, Lam CW-K. Apoptosis and B-cell lymphoma-2 of peripheral blood T lymphocytes and soluble Fas in patients with allergic asthma. Chest 2002;122:1751-1758.
33. Katoh S, Miyagi T, Taniguchi H, Matsubara Y, Kadota J, Tominaga A, Kincade PW, Matsukura S, Kohno S. An inducible sialidase regulates the hyaluronic acid binding ability of CD44-bearing human monocytes. J Immunol 1999;162:5058-5061.
34. Zhou DFH, Ding JF, Picker LJ, Bargatze RF, Butcher EC, Goeddel DV. Molecular cloning and expression of Pgp-1: the mouse homolog of the human H-CAM (Hermes) lymphocyte homing receptor. J Immunol 1989;143:3390-3395.
35. Akbari O, Stock P, Meyer E, Kronenberg M, Sidobre S, Nakayama T, Taniguchi M, Grusby MJ, DeKruyff RH, Umetsu DT. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med 2003;9:582-588.
36. Lesley J, Howes N, Perschl A, Hyman R. Hyaluronan binding function of CD44 is transiently activated on T cells during an in vivo immune response. J Exp Med 1994;180:383-387.
37. Nandi A, Estess P, Siegelman M. Bimolecular complex between rolling and firm adhesion receptors required for cell arrest: CD44 association with VLA-4 in T cell extravasation. Immunity 2004;20:455-465.
38. + Th1 and Th2 lymphocytes to roll and adhere. Blood 2006;107:4798-4806.
39. Shibamori M, Ogino K, Kambayashi Y, Ishiyama H. Intranasal mite allergen induces allergic asthma-like responses in NC/Nga mice. Life Sci 2006;78:987-994.
40. Chen C-L, Wang S-D, Zeng Z-Y, Lin K-J, Kao S-T, Tani T, Yu C-K, Wang J-Y. Serine protease inhibitors nafamostat mesilate and gebexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma. J Allergy Clin Immunol 2006;118:105-112.
41. Kato T, Takai T, Mitsuishi K, Okumura K, Ogawa H. Cystatin A inhibits IL-8 production by keratinocytes stimulated with Der p 1 and Der f 1: biochemical skin barrier against mite cysteine proteases. J Allergy Clin Immunol 2005;116:169-176.
42. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science 1998;282:2258-2261.
43. Taube C, Wei X, Swasey CH, Joetham A, Zarini S, Lively T, Takeda K, Loader J, Miyahara N, Kodama T, et al. Mast cells, FcεRI, and IL-13 are required for development of airway hyperresponsiveness after aerosolized allergen exposure in the absence of adjuvant. J Immunol 2004;172:6398-6406.
44. Jalkanen S, Jalkanen M, Bargatze RF, Tammi M, Butcher EC. Biochemical properties of glycoproteins involved in lymphocyte recognition of high endothelial venules in man. J Immunol 1998;141:1615-1623.
45. Jalkanen S, Jalkanen M. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J Cell Biol 1992;116:817-825.
46. Toyama-Sorimachi N, Kitamura F, Habuchi H, Tobita Y, Kimata K, Miyasaka M. Widespread expression of chondroitin sulfate-type serglycins with CD44 binding ability in hematopoietic cells. J Biol Chem 1997;272:26714-26719.
47. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin. Science 1996;271:509-512.
48. Hirabayashi J, Hashidate T, Arata Y, Nishi N, Nakamura T, Hirashima M, Urashima T, Oka T, Futai M, Muller WE, et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 2002;1572:232-254.
49. Bartolazzi A, Peach R, Aruffo A, Stamenkovic I. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med 1994;180:53-66.
50. Mikecz K, Brennan FR, Kim JH, Glant TT. Anti-CD44 treatment abrogates tissue edema and leukocyte infiltration in murine arthritis. Nat Med 1995;1:558-563.